Ricevi le ultime notizie sulle azioni Jaguar Health con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di JAGX

Ultime notizie per

Jaguar Health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Jaguar Health Inc

News

Press Releases

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Events

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Penny Stocks

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ADVM

AIIO

BANL

BNZI

CSE:PHOS

CSE:QQQ

EHGO

ELRRF

FRSPF

GOVX

IMRFF

JAGX

KSIOF

MDNAF

OMEX

QQCMF

RGBP

SIGY

SRFM

STKXF

STLNF

STNLF

TIVC

TSX:ELO

TSX:KSI

TSX:MDNA

TSXV:IMR

TSXV:SKP

TSXV:STUD

TSXV:VROY

USEG

VANI

VROYF

ZAPPF

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Biofrontera

Clearmind Medicine

CNS Pharma

Cocrystal Pharma

China Pharma Holding

Evoke Pharma

Gelteq

Impact BioMedical

IM Cannabis

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NLS Pharmaceutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Q/C Technologies

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TherapeuticsMD

VYNE Therapeutics

cbdMD

First Berlin

Comments

Jaguar Health Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO